What is Helix BioPharma Corp?
a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 132.13M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.